{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"The Myeloma Minutes","title":"033 MRD Explained: How Much Myeloma Is Really Left","html":"","width":"100%","height":180,"duration":1791,"description":"This episode explains minimal residual disease (MRD) - what it is, how it’s measured, and how it could shape more personalised myeloma treatment in the future.\n📌Key Takeaways:\n\nEven when blood tests look ‘normal’, tiny amounts of myeloma can still remain - MRD helps find it.\nReaching MRD negativity is a powerful sign - it often means longer, deeper remission.\nIn the future, MRD could decide when to stop, reduce or restart treatment - but we’re not quite there yet.\n\nFor extra content and more resources, please visit our website: https://www.themyelomaminutes.com/\nWe are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/\nThe Myeloma UK InfoLine is: 0800 980 3332\nThis podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns\n \nABOUT YOUR HOSTS\nDr. Jam Kothari\nDr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.\n \nDr. Sally Moore\nDr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an...","thumbnail_url":"https://img.transistorcdn.com/rD-uEWjDenF-XROyoth2QyT0dpCjh2HWCm0evlIF6_g/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wNDJl/MDM4NjA4NWE3NDkx/OTRkYzVkYzYxODIx/ZWI4YS5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}